Stem Cell Therapy for Chronic Kidney Disease
Recruiting in Palo Alto (17 mi)
+1 other location
Overseen byLaTonya Hickson, MD
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 1
Waitlist Available
Sponsor: LaTonya J. Hickson
No Placebo Group
Trial Summary
What is the purpose of this trial?
This trial is testing if using donor stem cells is safe and tolerable for people with chronic kidney disease. The stem cells might help repair their damaged kidneys. Stem cell therapy has shown potential in treating kidney diseases and aiding in kidney regeneration.
Eligibility Criteria
This trial is for adults aged 30-80 with chronic kidney disease, specifically those not on dialysis or with a transplant history. Participants must have certain levels of kidney function and protein in their urine, and can't be pregnant, heavy smokers, drug users, or have uncontrolled diseases like severe anemia.Inclusion Criteria
Ability to give informed consent
I am between 30 and 80 years old.
Your kidney function, as measured by eGFR, is between 25 and 55 ml/min/1.73m^2.
See 1 more
Exclusion Criteria
I am unable to understand and give consent for treatment.
I currently have an infection.
I have liver cirrhosis.
See 24 more
Treatment Details
Interventions
- Allogeneic adipose-derived mesenchymal stem cells (MSC)-Single Infusion (Mesenchymal Stem Cell Therapy)
- Allogeneic adipose-derived mesenchymal stem cells (MSC)-Two Infusions (Mesenchymal Stem Cell Therapy)
Trial OverviewThe study tests the safety of using stem cells from fat tissue to treat chronic kidney disease. Patients will receive either one or two infusions of these cells to see how well they tolerate them and any potential benefits.
Participant Groups
2Treatment groups
Experimental Treatment
Group I: Dose Arm 2Experimental Treatment1 Intervention
Subjects with chronic kidney disease will receive a single intravenous infusion of allogeneic adipose tissue-derived mesenchymal stem cells (MSC) of 150x10\^6 cells at day 0.
Group II: Dose Arm 1Experimental Treatment1 Intervention
Subjects with chronic kidney disease will receive allogeneic adipose tissue-derived mesenchymal stem cells (MSC) in two intravenous infusions of 75x10\^6 cells at day 0 and month 3.
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Mayo Clinic FloridaJacksonville, FL
Mayo Clinic in RochesterRochester, MN
Loading ...
Who Is Running the Clinical Trial?
LaTonya J. HicksonLead Sponsor